It was established that IL-6 was highly expressed in the inflammatory and tumor microenvironment and bound to IL-6R and gp130 to form a heterohexameric complex to initiate signaling pathways and induce activation of gp130-associated JAKs. The gene discussed is IL6; the disease is neoplasm.